



# Comparing the Efficacy of Sequential and Standard Quadruple Therapy for Eradication of *H. Pylori* Infection

Mohsen Razavizadeh, Abbas Arj\*, Maryam Madani, Hamidreza Gilassi

## ABSTRACT

**Background:** The aim of this study was comparison the effectiveness of sequential and standard quadruple therapy on eradication of *H. pylori* infection.

**Methods:** This clinical trial study was conducted on 160 patients with dyspepsia or gastroduodenal ulcer. Patients were randomly divided into two groups. Group A (standard regimen) received omeprazole, amoxicillin, clarithromycin and bismuth subcitrate for 2 weeks. Group B (sequential regimen) received omeprazole and amoxicillin in 5 days and omeprazole, tinidazole and levofloxacin in 5 days. After the end of treatment regimens, 20 mg omeprazole was administered twice daily for 3 weeks. *H. pylori* eradication was assessed 2 months after antibiotic treatment via fecal antigen.

**Results:** Frequency of *H. pylori* eradication in group A and B was observed in 55 (68.8%) and 63 patients (78.8%), respectively. No significant difference was seen between two groups, regarding *H. pylori* eradication ( $p = 0.15$ ). The most common side effects in group A, B were bitterness of mouth (63.8%) and nausea (16.2%), respectively ( $p < 0.001$ ).

**Conclusion:** Although no significant difference was seen between two groups regarding eradication of *H. pylori* infection, higher rate of *H. pylori* eradication was seen in group B than group A. Thus, sequential regimen was a more appropriate regimen with fewer complications.

## KEYWORDS

*H. pylori* infection; Sequential therapy; standard triple-drug therapy; eradication

## AUTHOR AFFILIATIONS

Department of Internal Medicine, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran

\* Corresponding author: Department of Internal Medicine, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran; e-mail [abbasarj2019@gmail.com](mailto:abbasarj2019@gmail.com)

Received: 17 January 2020

Accepted: 13 September 2020

Published online: 22 December 2020

Acta Medica (Hradec Králové) 2020; 63(4): 183–187

<https://doi.org/10.14712/18059694.2020.61>

© 2020 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## INTRODUCTION

*Helicobacter pylori* (*H. pylori*) infection is a worldwide and chronic infection. Its incidence is related to several factors including rate of acquisition of infection with *H. pylori*, rate of loss of the infection, and long-term survival of bacteria in the gastric mucosa between infection and eradication (1). *H. pylori* infection is associated with incidence of gastrointestinal diseases such as peptic ulcer, gastric inflammation and gastric cancer (2). It may lead to dyspeptic symptoms via changing the gastric acid secretion (3, 4), post-infective altering gastroduodenal mucosa and activating inflammation of gastric mucosa (4). The prevalence of *H. pylori* infection in developing countries is greater compared to developed countries (3). Furthermore, this prevalence varies in different countries and geographic regions of Asia (5). In this regard, prevalence rate in Japan, China, and Singapore is 39%, 58%, and 31%, respectively. Moreover, report of *H. pylori* infection rate is different in various areas of Iran (6-7).

Eradicating *H. pylori* prevents the recurrence of disease, decreases the risk of gastric cancer and heals peptic ulcers (8). In addition, after treating with antibiotics, other *H. pylori*-associated disorders including chronic atrophic gastritis, intestinal metaplasia and mucosa-associated lymphoid tissue can be regressed (8). However, an important issue in treatment of anti-*H. pylori* is antibiotic resistance (9) which has an effect on treatment efficacy (10).

Several regimens have been assessed for therapy of *H. pylori* infection in clinical trial studies (11-15). Despite many studies in this regard, the optimal therapeutic regimen is still unclear. Recently, common therapies rely on combination of antimicrobial factors such as levofloxacin, metronidazole, amoxicillin and proton pump inhibitors. Clarithromycin based regimens are considered as standard triple treatment. Recently, increasing resistance to standard antibiotic therapy for *H. pylori* infection has been reported (16-23).

Some studies have shown the performance of sequential therapy for eradication of *H. pylori* infection (24-26). In addition, many studies have shown superiority of sequential therapy on standard triple and quadruple therapy (22-27).

Given that prevalence of *H. pylori* infection in Iran is high (9) and few studies have evaluated efficacy of these two treatments as the first line therapy for *H. pylori* infection in our country, the aim of current study was comparison the effectiveness of sequential therapy and standard quadruple therapy on eradication of *H. pylori* infection.

## MATERIALS AND METHODS

This clinical trial study was conducted on patients with dyspepsia or gastroduodenal ulcer referred to Shahid Beheshti hospital, Kashan, Iran during 2018. After taking consent from patients, current research was approved by Kashan University of Medical Sciences.

Inclusion and exclusion criteria were as following.

## INCLUSION CRITERIA SELECTION

- Patients over 18 years old with dyspepsia or gastroduodenal ulcer
- Confirmation of *H. pylori* infection by fecal antigen or endoscopic pathological findings
- Willingness to participate in the study

## EXCLUSION CRITERIA SELECTION

- Previous eradication of *H. pylori*
- Use of any type of antibiotics and PPI during the 4 weeks prior to the study
- Pregnant and lactating women
- Patients with renal failure
- Patients with untreated heart failure
- Patients with history of gastrectomy or complicated peptic ulcer

Then, 160 patients were selected and randomly divided into two groups ( $n = 80$ ). Group A (standard 14-day treatment regimen) received omeprazole (20 mg b.d), amoxicillin (1 gr b.d), clarithromycin (500 mg b.d) and bismuth subcitrate (240 mg b.d) for 2 weeks. Group B (sequential regimens) received omeprazole (20 mg b.d) and amoxicillin (1 gr b.d) during 5 days and omeprazole (20 mg b.d), tinidazole (500 mg b.d) and levofloxacin (500 mg b.d) during 5 days (10 days). After the end of treatment regimens, 20 mg omeprazole was administered twice daily for 3 weeks.

*Helicobacter pylori* eradication was assessed at least 2 months after the end of antibiotic treatment or at least 2 weeks after omeprazole discontinuation via fecal antigen. Information including age, sex, history of *H. pylori* infection, history of non-steroidal anti-inflammatory drugs and alcohol intake and smoking were extracted from medical records.

## STATISTICAL ANALYSIS

Data were entered SPSS, version 19. Chi square test and Fisher exact test were used for analysis of data. P-value < 0.05 was considered statistically significant.

## RESULTS

In current study, 160 patients were classified to two groups. The mean age of patients in group A and B was  $45.92 \pm 14.18$  and  $41.43 \pm 13.61$  ( $p = 0.043$ ).

Other characteristics of patients in two groups are shown in Table 1.

As shown in Table 1, no significant difference was seen between two groups, in terms of characteristics such as sex, smoking, History of *H. pylori* infection and Taking non-steroidal anti-inflammatory drugs ( $p > 0.05$ ).

Frequency of *H. pylori* eradication in two groups is shown in Table 2.

As shown in Table 2, no significant difference was seen between two groups, regarding *H. pylori* eradication ( $p > 0.05$ ).

Frequency distribution of side effects in two groups is demonstrated in Table 3.

**Tab. 1** Characteristics of patients in two groups.

Variables	Standard regimen (A)	Sequential regimen (B)	p-value Chi Square test
Sex			
Men	36 (45%)	28 (35%)	0.197
Women	44 (55%)	52 (65%)	
Smoking	11 (13.8%)	6 (7.5%)	0.200
Taking NSAIDs	18 (22.5%)	20 (25%)	0.710
History of <i>H. pylori</i> infection	5 (6.2%)	7 (8.8%)	0.548

NSAIDs: Non-steroidal anti-inflammatory drug

**Tab. 2** Frequency of *H. pylori* eradication in two groups.

Eradication	Standard regimen N (%)	Sequential regimen N (%)	p-value Chi Square test
Yes	55 (68.8)	63 (78.8)	0.151
No	25 (31.2)	17 (21.2)	

**Tab. 3** Frequency distribution of side effects in two groups.

Complications	Standard regimen	Sequential regimen	p-value Fisher exact test
Headache	0 (0)	2 (2.5)	<0.001
Dizziness	0 (0)	3 (3.8)	
Bitterness of mouth	51 (63.8)	10 (12.5)	
Nausea	1 (1.2)	13 (16.2)	
Stomach ache	0 (0)	3 (3.8)	
Diarrhea	0 (0)	2 (2.5)	
Tendonitis	0 (0)	8 (10%)	
joint pain	0 (0)	2 (2.5)	
Skin lesions	0 (0)	1 (1.2)	
No complication	28 (35)	36 (45)	

As shown in Table 3, the most common side effect in group A and B was bitterness of mouth and nausea, respectively ( $p < 0.001$ ). Moreover significant differences was observed between two groups, regarding bitterness of mouth ( $p < 0.001$ ) (Chi square test).

Logistic regression analysis of studied variables is presented in Table 4.

After eliminating confounding effect of independent variables, there was no significant difference between two groups, regarding eradication of *H. pylori* infection (Table 4).

## DISCUSSION

*H. pylori* infection is not associated with symptoms in 50% of cases. However, some individuals develop inflammation of the gastritis or ulcers in the stomach or upper

**Tab. 4** Logistic regression analysis of studied variables in treatment of *H. pylori* infection.

	B	S. E.	Wald	df	P
Group	0.5210	0.381	1.866	1	0.172
Gender	0.0370	0.421	0.008	1	0.930
Age	-0.0060	0.013	0.189	1	0.664
NSAID taking	-0.0621	0.412	2.271	1	0.132
Smoking	-0.0327	0.627			
History of <i>H. pylori</i> infection	-0.0694	0.635	1.193	1	0.275
Constant	1.2870	0.712	3.272	1	0.070

small intestine (28–31). Moreover, *H. pylori* infection causes mortality and morbidity with an economic impact, thus requiring a proper therapeutic approach. Physicians usually treat stomach pain and ulcers created by *H. pylori* via combination of various antibiotics for several days. Recently, increasing resistance to standard antibiotic therapy for *H. pylori* infection was reported (16–22). Actually after standard therapy, infection was observed in one of every six patients with peptic ulcer disease. Therefore, *H. pylori* treatment is a challenge for physicians and no current first-line therapies are capable to treat the infection in all treated individuals (32). Based on findings of recent studies, sequential therapy is identified as first-line therapy in treatment of patients with *H. pylori* infection (32).

The findings of current study showed that the sequential regimen was superior to the quadruple therapy in the treatment of *H. pylori* infection, although no statistically significant were observed between two groups. In this study 78.8% of patients in sequential group and 68.8% of patients in quadruple diet group have recovered. Vaira et al., assessed sequential therapy versus standard triple therapy for eradication of *H. pylori*. The findings showed that eradication with sequential therapy was greater than standard therapy in these patients, which was consistent with our study (32).

Sánchez-Delgado et al., assessed ten-day sequential therapy for *H. pylori* eradication. They selected 139 patients and sequential regime consisted of a 10-day treatment such as a proton pump inhibitor b.d., 1 g b.d. amoxicillin for the first 5 days, followed by a PPI b.d., 500 mg b.d. clarithromycin and 500 mg b.d. metronidazole for the next 5 days. According to findings of this study, eradication was seen in 117 out of 129 patients who returned. It seems that sequential treatment is effective for eradicating *H. pylori* (33). Zhou et al., in China assessed sequential therapy regimen compared to conventional triple therapy for *H. pylori* eradication. Then, patients in group A received clarithromycin (500 mg), esomeprazole (20 mg) for the first 5 days, following esomeprazole (20 mg), clarithromycin (500 mg), amoxicillin (1000 mg) for the remaining 5 days. Group B received esomeprazole (20 mg), amoxicillin (1000 mg) for 5 days, followed by clarithromycin (500 mg), esomeprazole (20 mg), and amoxicillin (1000 mg) the remaining 5 days. The findings of this study showed that both treatments can alleviate symptoms in patients. Moreover, they believed that sequential therapy was better than standard

triple therapy (24). Marshall et al., compared efficacy of sequential therapy with standard triple therapies during 7–10 days. The findings showed that the success of sequential regimen was higher than standard triple therapies during 7–10 days (34). Gatta et al., reported eradication rate following triple therapy and sequential therapy were 35.1% and 83.9%, respectively (35).

Varia et al., reported 7–14 days triple therapy is reducing around the world with unsatisfactory low eradication rate in various country. They believed that sequential therapy is the most effective in first-line therapy and had superiority over standard triple therapy on more than 2300 treated patients. In addition, they reported that the sequential therapy is successful against those clarithromycin-resistant strains that have the A2143G point mutation, which significantly reduces the effectiveness of standard triple therapy (32). The precise mechanism of sequential therapy was unknown. There are several reasons, but all remain unconfirmed at this time.

One of the reasons is that reducing the bacterial density in the stomach via medications including amoxicillin and improving the efficacy of subsequently administered combination such as tinidazole and clarithromycin (36).

In addition, the most common side effects in group A and B was bitterness of mouth and nausea, respectively. Moreover, significant difference was observed between two groups, regarding side effects. Kaboli et al., compared sequential regimen and standard therapy for *H. pylori* eradication. The findings showed significant difference between two groups, regarding side effects, which was consistent with our study (37). Aminian et al., compared sequential regimen and standard quadruple therapy in patients with dyspepsia. The findings showed that there was significant difference between sequential regimen and standard quadruple regimen, considering side effects (38). This study also was consistent with our study.

It is noteworthy that the eradication rate of *Helicobacter pylori* in the two treatment groups was compared with controlling confounding variables of age, sex, use of non-steroidal anti-inflammatory drugs, smoking and family history of *Helicobacter pylori* infection via logistic regression analysis (Table 4). This caused to control the effect of confounding factors.

## CONCLUSION

Although no significant difference was seen between two groups in terms of eradication of *H. pylori* infection, higher rate of eradication of *H. pylori* infection was observed in sequential treatment regimens than standard regimens. Therefore, it was considered as a more appropriate treatment regimen compared to standard regimens in first-line therapy of *H. pylori* infection. In addition, this medication regimen was associated with fewer side effects.

## REFERENCES

1. Pounder RE, The prevalence of *Helicobacter pylori* infection in different countries. *Aliment Pharmacol Ther* 1995; 2: 33–9.
2. Yang J-Ch, Lu Ch-W, Lin Ch-J. Treatment of *Helicobacter pylori* infection: Current status and future concepts. *World J Gastroenterol* 2014; 20(18): 5283–93.
3. Fock KM, Ang TL. Epidemiology of *Helicobacter pylori* infection and gastric cancer in Asia. *J Gastroenterol Hepatol* 2010; 25: 479–86.
4. Malekzadeh R, Sotoudeh M, Derakhshan MH, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. *J ClinPathol* 2004; 57: 37–42.
5. Miftahussurur M. Population-Based Strategies for *Helicobacter pylori*-Associated Disease Management: Asian Perspective. *Helicobacter pylori Res* 2016; 519–42.
6. Fakheri H, Saberi Firoozi M, Bari Z. Eradication of *Helicobacter pylori* in Iran: A Review. *Middle East J Dig Dis* 2018; 10(1): 5–17.
7. Moosazadeh M, Lankarani KB, Afshari M. Meta-analysis of the Prevalence of *Helicobacter Pylori* Infection among Children and Adults of Iran. *Int J Prev Med* 2016; 7: 48.
8. Muhammad Mift M, Yoshio Yamaoka. Population-Based Strategies for *Helicobacter pylori*-Associated Disease Management: Asian Perspective. *Helicobacter pylori Res* 2015; 519–42.
9. Hosseini E, Poursina F, Van de Wiele T, GhasemianSafae Hi, Adibi P. *Helicobacter pylori* in Iran: A systematic review on the association of genotypes and gastroduodenal diseases. *J Res Med Sci* 2012; 17(3): 280–92.
10. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in *Helicobacter pylori*: A Systematic Review and Meta-analysis in World Health Organization Regions. *Gastroenterology* 2018; 155(5): 1372–82.e17.
11. Qasim A, Sebastian S, Thornton O, et al. Rifabutin- and furazolidone-based *Helicobacter pylori* eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. *Aliment Pharmacol Ther* 2005; 21: 91–6.
12. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. *Aliment Pharmacol Ther* 2005; 22: 45–9.
13. Gisbert JP, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in *Helicobacter pylori* eradication. *Helicobacter* 2005; 10: 157–71.
14. Fischbach LA, Van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-*Helicobacter pylori* quadruple therapies. *Aliment Pharmacol Ther* 2004; 20: 1071–82.
15. Graham DY, Hammoud F, El-Zimaity HM, et al. Meta-analysis: proton pump inhibitor or H2 receptor antagonist for *Helicobacter pylori* eradication. *Aliment Pharmacol Ther* 2003; 17: 1229–36.
16. Lee J, Breslin N. Treatment options for *Helicobacter pylori* infection when proton pump inhibitor-based triple therapy fails in clinical practice. *Aliment Pharmacol Ther* 1999; 13(4): 489–96.
17. Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxicillin and clarithromycin for the eradication of *Helicobacter pylori* in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. *Aliment Pharmacol Ther* 1998; 12(4): 383–8.
18. Deltenre M, Jonas C, van Gossum M, Buset M, Otero J, de Koster E. Omeprazole-based antimicrobial therapies: results in 198 *Helicobacter pylori*-positive patients. *European J Gastroenterol Hepatol* 1995; 7(1): S39–S44.
19. Kashimura H, Suzuki K, Hassan M, et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole amoxicillin and clarithromycin increases the cure rate of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 1999; 13(4): 483–7.
20. Wong FY, Chang S. Abid, et al. Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of *Helicobacter pylori* in duodenal ulcer patients in Asia and Africa. *Aliment Pharmacol Ther* 2000; 14(11): 1529–35.
21. Perri F, Villani M. Predictors of failure of *Helicobacter pylori* eradication with the standard. Maastricht triple therapy. *Aliment Pharmacol Ther* 2001; 15(7): 1023–9.
22. Ecclissato C, Marchioretto M, Mendonca S, et al. Increased primary resistance to recommended antibiotics negatively affects *Helicobacter pylori* eradication. *Helicobacter* 2002; 7: 53–9.
23. Rinaldi V, Zullo A. *Helicobacter pylori* eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. *Aliment Pharmacol Ther* 1999; 13(2): 163–8.
24. Zhou YQ, Xu L, Wang BF, et al. Modified sequential therapy regimen versus conventional tripletherapy for *Helicobacter pylori* eradication in duodenal ulcerpatients in China: a multicenter clinical comparative study. *Gastroenterol Res Pract* 2012; 405425.
25. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for *Helicobacter pylori* eradication: a randomized trial. *Ann Intern Med* 2007; 146(8): 556–63.

26. Sanchez-Delgado J, Calvet X, Bujanda L, Gisbert JP, Titó L, Castro M. Ten-day sequential treatment for *Helicobacter pylori* eradication in clinical practice. *Am J Gastroenterol* 2008; 103(9): 2220-3.
27. Yakut M, Cinar K, Seven G, Bahar K, Ozden A. Sequential therapy for *Helicobacter pylori* eradication. *Turk J Gastroenterol* 2010; 21(3): 206-11.
28. Megraud, F. *H. pylori* antibiotic resistance: prevalence, importance, and advances in testing. *Gut* 2004; 53(9): 1374-84.
29. Howden CW, Hunt RH. Guidelines for the management of *Helicobacter pylori* infection. *Am J Gastroenterol* 1998; 93(12): 2330-8.
30. Suerbaum S, Michetti P. *Helicobacter pylori* infection. *The New England J Med* 2002; 347: 1175-86.
31. Sipponen, P. Chronic Gastritis in former times and now. *Helicobacter* 2007; 2: 16-21.
32. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for *Helicobacter pylori* eradication: a randomized trial. *Ann Intern Med* 2007; 146(8): 556-63.
33. Sanchez-Delgado J, Calvet X, Bujanda L, Gisbert JP, Titó L, Castro M. Ten-day sequential treatment for *Helicobacter pylori* eradication in clinical practice. *Am J Gastroenterol* 2008; 103(9): 2220-3.
34. Marshall B. Sequential therapy for *Helicobacter pylori*: a worthwhile effort for your patients. *Ann Intern Med* 2008; 148: 962-3.
35. Gatta L, Di Mario F, Zullo A, Vaira D. Errors in a meta-analysis of treatments for *Helicobacter pylori* infection. *Ann Intern Med* 2008; 149: 686-76.
36. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for *Helicobacter pylori* infection: systematic review and meta-analysis of randomized controlled trials in adults and children. *Am J Gastroenterol* 2009; 104(12): 3069-79.
37. Kaboli AR. Comparison of Sequential Regimen and Standard Therapy for *Helicobacter pylori* Eradication in Patients with Dyspepsia. *Scientific J Hamadan Univ Med Sci* 2013; 20(3): 193-200.
38. Aminian K. Comparison of three-drug, four-drug and two different Sequential regimens in the treatment of first-line *Helicobacter pylori* infection. *Iranian J Infectious Dis* 2009; 1-9.